posted on 2021-06-04, 17:32authored byCaroline Schmidbauer, Michael Schwarz, Angelika Schütz, Raphael Schubert, Cornelia Schwanke, Enisa Gutic, Roxana Pirker, Tobias Lang, Thomas Reiberger, Hans Haltmayer, Michael Gschwantler
Abbreviations: SVR, sustained virologic response; SOF/VEL, sofosbuvir/velpatasvir; LTFU, lost to follow-up; SS, standard setting; DOT, directly observed therapy; HCV, hepatitis C virus; GT, genotype. A—All patients (n = 197/221). a including n = 2 patients who died for reasons not related to treatment after showing a negative HCV-RNA PCR result at week 2 of therapy and at the end of treatment, respectively. B—Patients with advanced fibrosis (n = 98/109). Advanced fibrosis was defined as F3-F4: ≥9.5 kPa according to transient elastography. b including 1 patient who died for reasons not related to treatment after showing a negative HCV-RNA PCR result at week 2 of therapy. C—Patients with HCV GT3 infection (n = 94/100).